Learn the recommended starting dose and titration strategy for tirzepatide in this medication review featuring Jennifer Mylod, DNP, from Arizona Arthritis & Rheumatology Associates in Phoenix, Arizona. This video provides a practical, clinician-focused overview of how to initiate tirzepatide at 2.5 mg once weekly to improve gastrointestinal tolerability and patient adherence, followed by a structured dose escalation approach. Viewers will gain insight into the standard titration schedule—advancing in 2.5 mg increments every 4 weeks up to a maximum of 15 mg—as well as how to individualize treatment based on patient response and side effect profile.

The discussion highlights common adverse effects such as nausea, vomiting, diarrhea, and constipation, along with strategies to manage these symptoms, including slower titration, dose adjustments, and patient counseling on diet, hydration, and meal size. This review also explores key clinical outcomes associated with tirzepatide, including glycemic control, weight reduction, and appetite regulation, while emphasizing that not all patients require maximum dosing to achieve meaningful benefits. Special considerations for older adults, patients with gastrointestinal sensitivity, renal impairment, or those on concomitant insulin or sulfonylureas are also addressed to help clinicians minimize risk and optimize safety.

Whether you're managing patients with type 2 diabetes or obesity, this video delivers actionable guidance on how to personalize tirzepatide therapy, improve tolerability, and support long-term treatment success. Explore more expert-led education and medication reviews on Content Rheum and stay up to date with the latest clinical insights in metabolic and rheumatologic care.

Stay up to date with the latest advancements in psoriatic arthritis treatment in this journal club review featuring Jessica Farrell, PharmD, from Albany Medical Center. This video explores a Phase 3 SOLSTICE clinical trial evaluating the efficacy and safety of guselkumab in patients with active psoriatic arthritis who had an inadequate response to a prior TNF inhibitor.

The discussion highlights key clinical outcomes, including ACR20, ACR50, and ACR70 response rates, minimal disease activity, and psoriasis improvement, demonstrating that guselkumab significantly outperformed placebo across multiple endpoints. Importantly, the review examines dosing strategies, comparing every-4-week versus every-8-week regimens, and explains why increased dosing frequency did not lead to superior outcomes—offering valuable insights into pharmacokinetics and receptor saturation in IL-23 inhibition.

Designed for healthcare professionals managing complex psoriatic arthritis cases, this video provides practical, evidence-based guidance on biologic sequencing after TNF failure, real-world applicability of clinical trial data, and how to optimize treatment strategies for improved patient outcomes. For more expert-led education, visit the Content Rheum and stay up to date with the latest clinical insights in rheumatologic care.

In this educational FAQ video, Wendy Simmons, PA-C from Carolina Arthritis Associates, shares expert insights on hypophosphatasia (HPP)—a rare genetic metabolic bone disorder that is frequently underrecognized in rheumatology practice. With over 25 years of experience in rheumatology and specialization in osteoporosis, she highlights how HPP is characterized by low alkaline phosphatase levels and impaired bone mineralization, leading to chronic pain, fractures, and reduced quality of life. This comprehensive discussion explores why patients with HPP are often misdiagnosed with more common conditions such as fibromyalgia, osteoarthritis, neuropathies, or even psoriatic arthritis, and emphasizes the importance of recognizing overlapping, cross-specialty symptoms.

Wendy outlines key clinical pearls to help advanced practice providers and healthcare professionals improve early diagnosis, including the importance of obtaining a detailed childhood history, dental history (early tooth loss with intact roots), and careful interpretation of alkaline phosphatase lab values across adult and pediatric ranges. She also discusses hallmark fracture patterns such as metatarsal stress fractures and atypical femur fractures, as well as the significant diagnostic delay—often averaging over a decade—that many patients experience. This video serves as a practical guide for clinicians to better identify HPP, avoid common diagnostic pitfalls, and ultimately improve patient outcomes through earlier recognition and appropriate management.

Perfect for rheumatology APPs, physician assistants, nurse practitioners, and clinicians interested in rare bone diseases, osteoporosis, and metabolic disorders, this video reinforces the importance of a thorough clinical history, targeted lab evaluation, and heightened awareness of hypophosphatasia in everyday practice. For more expert-driven APP education, visit the RhAPP Content Rheum or access resources through the RhAPP ACE app.